ENERGENESIS BIOMEDICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54 TWD | -0.55% |
|
-2.17% | -10.60% |
| Apr. 08 | Energenesis Biomedical CO.,LTD. announced a financing transaction | CI |
| Feb. 29 | Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 7.35M 227K | Sales 2023 | 7.16M 221K | Capitalization | 4.59B 142M |
|---|---|---|---|---|---|
| Net income 2022 | -266M -8.2M | Net income 2023 | -260M -8.02M | EV / Sales 2022 | 324 x |
| Net cash position 2022 | 475M 14.65M | Net cash position 2023 | 691M 21.31M | EV / Sales 2023 | 545 x |
| P/E ratio 2022 |
-10.7
x | P/E ratio 2023 |
-16.7
x | Employees | 35 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.22% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.55% | ||
| 1 week | -2.17% | ||
| Current month | -2.88% | ||
| 1 month | -13.88% | ||
| 3 months | -10.60% | ||
| 6 months | -21.51% | ||
| Current year | -10.60% |
1 week
54.00
55.80
1 month
51.5062.30
Current year
51.5063.90
1 year
51.5099.50
3 years
30.9099.50
5 years
30.90102.00
10 years
28.51102.00
| Managers | Title | Age | Since |
|---|---|---|---|
Han Min Chen
FOU | Founder | - | 12-08-27 |
Pei Chao Chen
DFI | Director of Finance/CFO | - | 20-05-24 |
Yi-fang Cheng
CTO | Chief Tech/Sci/R&D Officer | - | 13-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shou Shan Wu
BRD | Director/Board Member | 74 | 19-05-05 |
Jen Yi Chiu
FOU | Founder | - | 12-08-27 |
Han Min Chen
FOU | Founder | - | 12-08-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 54 | -0.55% | 17,361 |
| 24-05-09 | 54.3 | +0.56% | 67,383 |
| 24-05-08 | 54 | -1.28% | 47,462 |
| 24-05-07 | 54.7 | -0.36% | 76,079 |
| 24-05-06 | 54.9 | -0.54% | 117,301 |
End-of-day quote Taiwan S.E., May 09, 2024
More quotes
ENERGENESIS BIOMEDICAL CO., LTD. is mainly engaged in the research and development of new drugs. The Company's main product projects include experimental service analysis and reagent sales. The Company's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.60% | 127M | |
| +17.96% | 47.02B | |
| +48.77% | 41.86B | |
| +1.17% | 41.76B | |
| -4.27% | 28.8B | |
| +11.42% | 26.05B | |
| -21.39% | 19.15B | |
| +4.86% | 12.55B | |
| +27.29% | 12.34B | |
| -3.50% | 11.82B |
- Stock Market
- Equities
- 6657 Stock